INGN logo

Inogen, Inc. Stock Price

NasdaqGS:INGN Community·US$187.9m Market Cap
  • 3 Narratives written by author
  • 2 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

INGN Share Price Performance

US$6.94
-0.09 (-1.28%)
US$12.67
Fair Value
US$6.94
-0.09 (-1.28%)
45.2% undervalued intrinsic discount
US$12.67
Fair Value
Price US$6.94
AnalystConsensusTarget US$12.67
AnalystLowTarget US$12.00
AnalystHighTarget US$14.00

INGN Community Narratives

·
Fair Value US$12.67 45.2% undervalued intrinsic discount

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

0users have liked this narrative
2users have commented on this narrative
6users have followed this narrative
·
Fair Value US$12 42.2% undervalued intrinsic discount

Pricing Pressures And Rivals Will Erode Portable Oxygen Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$14 50.4% undervalued intrinsic discount

Aging Global Population And At-Home Care Will Boost Market Demand

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$12.67
45.2% undervalued intrinsic discount
Profit Margin
12.11%
Future PE
8.54x
Price in 2029
US$15.67
US$14
50.4% undervalued intrinsic discount
Profit Margin
12.32%
Future PE
11.21x
Price in 2028
US$17.36

Trending Discussion

Updated Narratives

INGN logo

INGN: Bullish Initiation And New CFO Will Support Future Upside

Fair Value: US$12 42.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INGN logo

INGN: Bullish Initiation And Buyback Program Will Support Future Upside

Fair Value: US$12.67 45.2% undervalued intrinsic discount
6 users have set this as their fair value
2 users have commented on this narrative
0 users have liked this narrative
INGN logo

Aging Global Population And At-Home Care Will Boost Market Demand

Fair Value: US$14 50.4% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with excellent balance sheet.

1 Risk
3 Rewards

Inogen, Inc. Key Details

US$351.5m

Revenue

US$195.7m

Cost of Revenue

US$155.8m

Gross Profit

US$180.7m

Other Expenses

-US$24.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.92
44.31%
-7.08%
0%
View Full Analysis

About INGN

Founded
2001
Employees
753
CEO
Kevin R. Smith
WebsiteView website
www.provider.inogen.com

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

Recent INGN News & Updates

Narrative Update Jun 17

INGN: Bullish Initiation And New CFO Will Support Future Upside

Analysts have kept their $12.00 price target on Inogen steady, pointing to updated assumptions around discount rates, revenue growth, profit margins, and future P/E that are broadly consistent with prior views and supported by recent bullish Street research. What’s in the News for Inogen Inogen issued earnings guidance for the second quarter of 2026, with expected reported revenue between $94 million and $97 million, and stated that this range reflects approximately 3.5% growth at the midpoint relative to second quarter 2025 revenue (source: company guidance).
Narrative Update Jun 03

INGN: Bullish Initiation And New CFO Will Support Future Returns

Analysts have maintained Inogen's fair value estimate at $12.00, tying the unchanged price target to a new bullish initiation that emphasizes the stock's outlook while modestly adjusting assumptions around the discount rate, revenue growth, profit margin, and future P/E. What's in the News Inogen issued earnings guidance for the second quarter of 2026, with expected reported revenue between US$94 million and US$97 million.

Recent updates

No updates